Skip to content

Warby Parker WRBY Deferred Tax Assets, Valuation Allowance

Deferred Tax Assets, Valuation Allowance at other companies

Bausch + Lomb logo
Bausch + LombBLCO
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Revenue$242.4M+8.3%
Gross profit$131.0M+4.0%
Operating income$1.7M-32.5%
Net income$3.2M-8.5%
EPS (diluted)$0.030.0%

Balance sheet

See full
Cash & equivalents$288.2M+8.7%
Total debt$237.6M+6.2%
Total equity$375.8M+6.1%
Total assets$736.4M+7.9%

Cash flow

See full
Operating cash flow$24.5M-16.5%
CapEx$16.1M-0.1%
Free cash flow$8.4M-36.6%

Valuation

See full
Market cap$3.15B+17.1%

Profitability

See full
Gross margin53.4%-1.8pp
Operating margin-0.7%-0.3pp
Net margin0.1%0.0pp
FCF margin4.5%-0.8pp

Returns & leverage

See full
Return on equity0.2%+0.1pp
Debt / equity0.6×0.0×
Current ratio2.3×-0.4×

Where this comes from

Reported directly by Warby Parker in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.

The official record: Warby Parker’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Warby Parker's deferred tax assets, valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Warby Parker's deferred tax assets, valuation allowance?
Warby Parker (WRBY) reported deferred tax assets, valuation allowance of $56.29M in Q4 2025.
How has Warby Parker's deferred tax assets, valuation allowance changed year-over-year?
Warby Parker's deferred tax assets, valuation allowance decreased by 17.8% year-over-year, from $68.5M to $56.29M.
What is the long-term trend for Warby Parker's deferred tax assets, valuation allowance?
Over 5 years (2020 to 2025), Warby Parker's deferred tax assets, valuation allowance has grown at a 4.9% compound annual growth rate (CAGR), from $44.3M to $56.29M.